PortfoliosLab logoPortfoliosLab logo
ONCT vs. NTLA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ONCT vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Oncternal Therapeutics, Inc. (ONCT) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


ONCT

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

NTLA

1D
-0.84%
1M
-6.13%
YTD
44.83%
6M
43.71%
1Y
69.31%
3Y*
-31.75%
5Y*
-29.01%
10Y*
-7.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ONCT vs. NTLA - Yearly Performance Comparison


Correlation

The correlation between ONCT and NTLA is -0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (All Time)
Calculated using the full available price history since Feb 9, 2026

-0.05

Fundamentals

Total Revenue (TTM)

ONCT:

$1.67M

NTLA:

$66.09M

Gross Profit (TTM)

ONCT:

-$16.96M

NTLA:

-$33.92M

EBITDA (TTM)

ONCT:

-$17.87M

NTLA:

-$299.32M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ONCT vs. NTLA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ONCT

NTLA
NTLA Risk / Return Rank: 6363
Overall Rank
NTLA Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
NTLA Sortino Ratio Rank: 6565
Sortino Ratio Rank
NTLA Omega Ratio Rank: 6868
Omega Ratio Rank
NTLA Calmar Ratio Rank: 6161
Calmar Ratio Rank
NTLA Martin Ratio Rank: 5656
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ONCT vs. NTLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Oncternal Therapeutics, Inc. (ONCT) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

ONCT vs. NTLA - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


ONCTNTLADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.73

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.36

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.10

Sharpe Ratio (All Time)

Calculated using the full available price history

1.68

-0.07

+1.75

Drawdowns

ONCT vs. NTLA - Drawdown Comparison

The maximum ONCT drawdown since its inception was 0.00%, smaller than the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for ONCT and NTLA.


Loading charts...

Drawdown Indicators


ONCTNTLADifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-96.45%

+96.45%

Max Drawdown (1Y)

Largest decline over 1 year

-71.27%

Max Drawdown (3Y)

Largest decline over 3 years

-86.36%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

Max Drawdown (10Y)

Largest decline over 10 years

-96.45%

Current Drawdown

Current decline from peak

0.00%

-92.63%

+92.63%

Average Drawdown

Average peak-to-trough decline

0.00%

-57.04%

+57.04%

Ulcer Index

Depth and duration of drawdowns from previous peaks

44.93%

Volatility

ONCT vs. NTLA - Volatility Comparison


Loading charts...

Volatility by Period


ONCTNTLADifference

Volatility (1M)

Calculated over the trailing 1-month period

18.74%

Volatility (6M)

Calculated over the trailing 6-month period

53.80%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

95.55%

-95.55%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

80.62%

-80.62%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

78.25%

-78.25%

Dividends

ONCT vs. NTLA - Dividend Comparison

Neither ONCT nor NTLA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ONCT vs. NTLA - Financials Comparison

This section allows you to compare key financial metrics between Oncternal Therapeutics, Inc. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-5.00M0.005.00M10.00M15.00M20.00M25.00M30.00M202220232024202520260
15.05M
(ONCT) Total Revenue
(NTLA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ONCT and NTLA have a correlation of -0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for ONCT and NTLA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer